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CC BY-NC-ND license (http://creativeBackground/purpose: Congenital hyperinsulinism (CHI) is a rare condition causing severe hypo-
glycemia in neonates and infants due to dysregulation of insulin secretion. This study aimed to
review 20 years’ experience in the management of Taiwanese children with CHI.
Methods: Between 1990 and 2010, children diagnosed with CHI and followed up at the Pediat-
ric Endocrine Clinic of the National Taiwan University Hospital were enrolled. Their medical
records were thoroughly reviewed.
Results: In total, 13 patients (8 boys and 5 girls) were enrolled, including six patients with onset of
hypoglycemiawithin1monthofageand sevenpatients at 4.0 2.1monthsofage. Thebirthweight
standard deviation scores of these two age groups were 4.6 1.8 and 1.4 1.3 standard deviation
score, respectively (p< 0.01). Initial intravenous glucose infusion at rates of 22.9 5.3mg/kg/min
and 13.4  5.6 mg/kg/min, respectively, were mandatory to maintain euglycemia in these two
groups (p < 0.05). All received pancreatectomy after failure of initial medical treatment. Twelve
patients were followed up for a period of 2.5e19.8 years. Eight of them remained euglycemic
without anymedication and three patients developeddiabetesmellitus. Sevenof the nine patients
who underwent intelligence evaluation had normal mental outcomes. Mental retardation of two
patients was too severe to be evaluated. All four patients with mental retardation had a delay in
the maintenance of euglycemia, and three of them also had seizure disorder.
Conclusion: The age at onset of hypoglycemia reflects the severity of CHI. Early diagnosis and
appropriate treatment are important for favorable mental outcomes.have no conflicts of interest relevant to this article.
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4.0/).Introduction (range, 2.5e19.8 years). Only one patient was lost to follow
up after discharge at the age of 1.6 months. During followCongenital hyperinsulinism (CHI), previously known as
persistent hyperinsulinemic hypoglycemia of infancy or
nesidioblastosis, refers to the condition of severe hypogly-
cemia in neonates and infants caused by dysregulated in-
sulin secretion.1 The incidence of CHI is estimated to range
from one case/40,000e50,000 live births in northern
Europe2,3 to one case/3000 live births in Saudi Arabia,4 an
area with a high rate of consanguinity. Both dominant and
recessive inheritances have been reported. The molecular
genetic basis of CHI has been elucidated, and mutations in
genes of ABCC8, KCNJ11, GLUD1, GCK, HADH, HNF4A,
SLC16A1, and UCP2 have been reported in patients with
CHI. Nonetheless, these mutations account for only about
half of the CHI cases.5
Pathologies of CHI can be divided into diffuse and focal
forms. The most common genetic causes of diffuse-type CHI
are recessive mutations in the genes ABCC8 and KCNJ11
that encode the SUR1 and Kir6.2 subunits of adenosine
triphosphate (ATP)-sensitive Kþ channels (KATP channel) of
the pancreatic b-cell.5e7 Focal CHI results from a paternally
inherited KATP channel mutation together with somatic loss
of the maternal chromosome 11p15 region.8
Hyperinsulinism can suppress the production of ketone
bodies, which are alternative fuel for the brain, and there
may be severe neurologic damage if treatment is delayed.
Pharmacologic therapies with diazoxide,9 octreotide,10,11
calcium channel blockers,12 or glucagon13,14 have been
tried, however, results vary due to the heterogeneity of
underlying diseases. Those who do not respond to the
conservative therapy need pancreatectomy to prevent
irreversible brain damage due to persistent hypoglycemia.
Owing to a paucity of information on CHI in Taiwanese
children, this study was conducted to elucidate experi-
ences in the management of CHI in 13 Taiwanese children.
Patients and methods
Medical records of 13 children diagnosed with CHI at the
National Taiwan University Hospital between 1990 and 2010
were reviewed. The diagnostic criteria were modified from
those of the European Network for Research into Hyperin-
sulinism15: (1) laboratory blood glucose level of <50 mg/dL;
(2) glucose requirement >6e8 mg/kg/min to maintain a
blood glucose level of >50 mg/dL; (3) detectable insulin at
the point of hypoglycemia, with raised C-peptide; (4)
inappropriately low ketone body concentrations at the time
of hypoglycemia; and (5) glycemic response after glucagon
administration during hypoglycemia. Patients with Beck-
witheWiedemann syndrome, congenital disorders of
glycosylation, or insulinoma were excluded.
Among the patients, 11 were referred from other hos-
pitals because of poorly controlled hypoglycemia. Twelve
patients were followed up at the Pediatric Endocrine Clinic
of National Taiwan University Hospital and Kaohsiung Vet-
erans General Hospital for a median period of 11.6 yearsup, their blood glucose status was evaluated by regular
checking of fasting blood glucose and HbA1c levels. Clinical
neurological function was evaluated and electroencepha-
lography examination was performed. Psychometric intel-
ligence was assessed using the Chinese version of the
Wechsler Intelligence Scale for Children, third edition, or
the Wechsler Pre-school and Primary Scale of Intelligence-
Revised in nine patients. An intelligence quotient (IQ) of
50e69 was classified as mild mental retardation.
Statistical analysis
Numerical variables were expressed as mean  standard
deviation. Differences in the continuous variables were
evaluated using nonparametric ManneWhitney U test, and
categorical variables were analyzed using chi-square test or
Fisher’s exact test. Statistical significance was set at
p < 0.05. All statistical analyses were performed using the
Statistical Program for Social Science 15.0 (SPSS Inc., Chi-
cago, IL, USA).
Results
Clinical characteristics
None of the total 13 patients (8 boys and 5 girls) had any
family history of CHI or consanguinity. Except for one pa-
tient who was born at 36 weeks of gestation, all the others
were born at full term. Ten patients (77%) had macrosomia
and nine patients (69%) had seizures as their initial pre-
sentation. Other initial presentations included hypotonia
(62%), hypoactivity (54%), consciousness disturbance (46%),
irritability (46%), poor sucking/poor feeding (23%), cyanosis
(15%), sweating (15%), apnea (8%), tremor (8%), and
myoclonus (8%). By contrast, two asymptomatic patients
were detected by routine glucose screening for
macrosomia.
In terms of age at onset of symptoms, six of 13 patients
(46%) had onset of hypoglycemia in the neonatal period
(Table 1). Among them, four patients had onset within 24
hours after birth. Their age at diagnosis ranged from 1 day
to 12 days. The other seven patients (54%) had onset of
hypoglycemia in infancy, at a mean age of 4 months (range,
2e8 months), and were diagnosed at a mean age of 7
months (range, 2 monthse1.6 years).
The birth weight standard deviation scores (SDS) of pa-
tients in the neonatal-onset group (age at onset <1 month)
and those in infantile-onset group (age at onset >1 month)
were 4.6  1.8 and 1.4  1.3, respectively (p < 0.01). All six
patients in the neonatal-onset group had birth weight SDS
>2, while only two of seven patients in the infantile-onset
group (29%) had birth weight SDS >2 (p < 0.01).
Upon diagnosis, the median level of their lowest docu-
mented glucose level was 20 mg/dL (range, 5e35 mg/dL)
and the median level of their highest documented insulin
Table 1 Clinical characteristics of patients with congenital hyperinsulinism.
Patient
no.
Sex Birth
weight
(gram)
Age at
presentationa
Age at
diagnosisa
Lowest
glucose
level
(mg/dL)
Highest
insulin
level
(mU/mL)
Maximum
I/G ratio
Initial
max SIRb
(mg/kg/min)
Operation Pathology Outcomed
Agea Typec
1 F 4550 <1 d 1 d 27 >400 10.81 30.0 13 d NP diffuse (-)
2 M 5664 <1 d 1 d 22 37.3 1.07 25.3 1 m NP diffuse DM
3 F 3960 <1 d 7 d 31 20 0.46 21.0 22 d NP diffuse (-)
4 F 4310 <1 d 9 d 5 155.8 21.14 23.0 18 d NP diffuse (-)
5 M 4100 1 d 12 d 18 62.7 2.41 24.0 8 m NP diffuse DM, MR
6 M 5840 2 d 2 d 34 37.4 1.01 14.0 1 m NP diffuse DM
7 F 4120 2 m 2 m 35 20.1 0.56 11.3 2 m NP diffuse MR
8 M 3900 2 m 2 m 24 119 2.9 11.6 9 m SP diffuse (-)
9 M 3920 3 m 5 m 15 6.1 0.21 15.0 6 m EN focal (-)
10 M 3670 4 m 6 m 20 21.2 0.63 13.0 6 m NP diffuse MR
11 F 4300 4 m 11 m 12 48.5 1.31 25.0 1 y NP diffuse (-)
12 M 3000 5 m 1.6 y 12 46.8 3.11 10.0 1.9 y SP diffuse MR
13 M 3400 8 m 10 m 18 31.4 0.73 8.0 1.3 y NP diffuse (-)
a d: day; m: month; y: year.
b Max SIR: maximum glucose infusion rate.
c NP: near total pancreatectomy; SP: subtotal pancreatectomy; EN: enucleation.
d (-): neither DM nor MR detected; DM: diabetes mellitus; MR: mental retardation.
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dian level of their maximal documented insulin to glucose
(I/G) ratio was 1.07 (range, 0.21e21.14) (Table 1). Patients
of the neonatal-onset group and those of the infantile-
onset group had no significant difference in the lowest
documented glucose level, highest documented insulin
level, and maximal I/G ratio. The patient with the lowest I/
G ratio (Patient 9) had the focal form of CHI. In none of the
patients was hyperammonemia detected during episodes of
hypoglycemia.
Management
Intravenous glucose infusion at a rate of 17.8  7.2 mg/kg/
min was required to maintain blood glucose levels of
>50 mg/dL. The glucose infusion rate was significantly
higher in the neonatal-onset group than in the infantile-
onset group (22.9  5.3 mg/kg/min vs. 13.4  5.6 mg/kg/
min, p < 0.05) (Table 1).
Diazoxide (10e20 mg/kg/d) was given in seven patients,
and nifedipine was tried in one patient after diagnosis, but
without relief. Pancreatectomy was performed in all 13
patients at a median age of 6 months (range, 13 dayse1.9
years) (Table 1). All six patients with neonatal-onset CHI
and four of the seven patients with infantile-onset CHI had
near-total pancreatectomy (>95% of the pancreas
removed). Two patients had subtotal pancreatectomy
(80e94% of the pancreas removed).
Twelve patients were confirmed to have diffuse lesions
by pathological examination. The remaining patient (Pa-
tient 9) had only the lesion at the body of the pancreas
removed, which was proved to be focal adenomatous hy-
perplasia. One patient (Patient 3) had ectopic pancreas at
the gastric pylorus, aside from the pancreatic lesion. The
heterotopic lesion also had islet cell hyperplasia, similar to
the pancreatic lesion.Five patients, including the patient with the focal form
of CHI, became euglycemic after pancreatectomy. One
patient (Patient 2) developed diabetes mellitus (DM)
immediately after surgery. Seven patients still had hypo-
glycemic episodes after surgery and were treated with
diazoxide. Among them, four were in the neonatal-onset
group and three in the infantile-onset group. Their differ-
ence was not statistically significant (67% vs. 43%,
p Z 0.592).
Two of these seven patients had poor response to diaz-
oxide, and they were shifted to octreotide. Of the other
five patients, three achieved long-term stable glycemic
control by diazoxide alone and two were treated with
octreotide in addition to diazoxide for a period after
pancreatectomy. One of them (Patient 7) still had recurrent
episodes of hypoglycemia until the age of 1 year (10 months
after pancreatectomy).
Long-term outcome
Among the seven patients with continued medical treat-
ment after surgery, six stopped the medical treatment
between 2.2 years and 10.6 years of age, and had no epi-
sodes of hypoglycemia. Only one patient (Patient 13)
continued diazoxide therapy until the end of the study. Two
patients developed hypertrichosis after diazoxide treat-
ment and other two patients developed gallbladder sludge
following octreotide treatment. No other serious adverse
drug effect was elicited in other patients. In terms of
postoperative complications, none had steatorrhea
although one patient had mild fat intolerance. One patient
(Patient 5) had recurrent adhesion ileus.
Of the 12 patients with long-term follow up, eight
remained euglycemic until the end of the study even
without any medication. One patient continued diazoxide
therapy, while three patients had DM at the end of the
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after surgery at the age of 1.1 months, while two patients
(Patients 5 and 6) had DM at the age of 10.6 years and 12.3
years, respectively.
Two of 12 patients with long-term follow up had mental
retardation (Patients 10 and 12) that was too severe for an
IQ test, while one (Patient 3) was too young to undergo an
IQ test but had normal neurological development during the
2.5 years of follow up. The other nine patients had IQ
evaluated at a median age of 6.7 years (range, 3.3e12.2
years). Seven of nine patients had normal IQ, and the other
two (Patients 5 and 7) had mild mental retardation. Among
four patients with mental retardation, one (Patient 5) had
neonatal-onset CHI and the other three had infantile-onset
CHI.
In the four patients with mental retardation, mainte-
nance of euglycemia was delayed for a period ranging from
2 months to 18 months after onset of symptoms. Delays in
gross motor development were detected in three patients.
Four (33%) of 12 patients with long-term follow up had
seizure disorder, which was controlled using anticonvul-
sants. Three of them also had mental retardation.Discussion
Clinical characteristics and long-term outcome of Taiwa-
nese children with CHI were reviewed in this study. There
were significant differences in birth weight and initial
glucose requirement between the neonatal-onset and the
infantile-onset groups. Because all six patients in the
neonatal-onset group had symptoms within 2 days after
delivery and a high demand of glucose was noted after
birth, their macrosomia was thought to be due to severe
prenatal hyperinsulinism. Similarly, Meissner et al16 re-
ported a trend of higher birth weight SDS in patients with
neonatal onset than in those with manifestation in infancy
or childhood. The age at onset and initial glucose require-
ment in patients with CHI thus reflected the severity of
hyperinsulinism. Meissner et al16 also reported that 27% of
patients with neonatal-onset CHI had birth weight SDS >2.
In this study, all six patients in the neonatal-onset group
had birth weight SDS >2, implying that patients with
neonatal-onset CHI were at the severe end of the spectrum
of CHI.
An I/G ratio of >0.3e0.5 during hypoglycemia is
considered a diagnostic criterion for CHI.9,17,18 However,
one of the 13 patients had a maximal I/G ratio of <0.3.
Some cases may be missed if diagnosis is based only on an
I/G ratio of >0.3 as the gold standard for diagnosing CHI.
Such an idea has also been raised by another study.19 Thus,
for the diagnosis of CHI, it is prudent to consider other
clinical parameters such as high glucose demand, low blood
ketone body level, and positive glycemic response to
glucagon during episodes of hypoglycemia.
One patient with pancreatic focal adenomatous hyper-
plasia had remission of hypoglycemia after resection of the
focal lesion, while others with the diffuse form of CHI
needed extensive pancreatectomy to control hypoglyce-
mia. Thus, differentiating between focal and diffuse forms
is important before surgery.20 Pancreatic venous blood
sampling using transhepatic catheterization with orwithout pancreatic arterial calcium stimulation has been
reported to locate pancreatic lesions.20,21 However, such a
procedure is invasive and technically demanding, there-
fore, it is not widely used. Noninvasive fluorine-18 L-3,4-
dihydroxyphenylalanine ([18F]-DOPA) positron emission to-
mography (PET) has been applied to localize pancreatic
lesions based on the neuroendocrine nature of pancreatic
islet cells.22 However, the accuracy of [18F]-DOPA PET
varies between studies.23,24 Because the patients in this
study were worked up before [18F]-DOPA PET was made
available in our hospital, they were not studied using [18F]-
DOPA PET.
Despite aggressive treatment, four of the 11 patients
with CHI (36%) still developed mental retardation. Three
also had seizure disorder. These findings are similar to other
reports.16,25 Menni et al25 reported that neonatal-onset CHI
was the main risk factor for mental retardation. However,
our study shows a higher percentage of mental retardation
in patients with infantile-onset CHI, which is similar to that
reported by Meissner et al.16 Because maintenance of
euglycemia is important in preventing mental retardation in
these patients, brain damage by undetected hypoglycemia
in infantile-onset CHI may explain such a phenomenon.
Difference in study populations may also account for such a
discrepancy.
DM is a long-term complication of CHI.16,20,26,27 In non-
pancreatectomized patients, glucose intolerance or DM
may occur after their teenage years.26 By contrast, DM also
occurs in patients treated with near-total pancreatectomy.
It may occur immediately after surgery or before the 2nd
decade of life.16,20,27 In this series, three of 12 patients
(25%) had DM. One patient developed DM immediately
postoperatively, and two patients had DM at the age of 10.6
years and 12.3 years. All of them had neonatal-onset CHI
and were treated with near-total pancreatectomy. All other
nine patients, aged 2.5e20 years, had no evidence of DM by
the end of follow up. However, monitoring of their glucose
levels was indicated for early detection of DM.
In summary, this study demonstrates clinical character-
istics and long-term outcome of Taiwanese children with
CHI. Our results showed that macrosomia and irritability of
the nervous system were important clinical clues to the
diagnosis of CHI Our data also showed that the I/G ratio,
used as a diagnostic criterion of CHI, was not so reliable as
previously reported. Therefore, it is prudent to work up on
patients with detectable serum insulin levels during the
episode of hypoglycemia in order to prevent delayed diag-
nosis of CHI. Early diagnosis and appropriate treatment to
maintain euglycemia remain the mainstay of management
to prevent mental retardation of patients with CHI. We
hope that the experience cited here can help physicians
identify patients with CHI and institute appropriate man-
agement to improve outcome.References
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